Regeneron Pharma strong Q3 driven by robust Dupixent and Libtayo sales

• Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 results:
• Revenues: $2,294M (+32%); Eylea total sales: $2,098.3M (+9%); Dupixent global net sales: $1,072.6M (+69%); Libtayo global sales: $96.1M (+87%); Praluent: $91.5M (+31%); Kevzara: $70M (+28%); REGN-COV2: $40.2M.
• Net Income: $842M (+26%); EPS: $7.39 (+26%); non-GAAP Net Income: $961M (+26%); non-GAAP EPS: $8.36 (+25%).
• Net cash used in operations (3 months): $254.3M.
• The Company had robust top and bottom line growth driven by EYLEA in retinal diseases and Dupixent in atopic dermatitis and asthma.
• In 2021, REGN looks forward to potential launches including PD-1 inhibitor Libtayo in non-small cell lung cancer and advanced basal cell carcinoma.
• Lastly, Regeneron's novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola.
• https://seekingalpha.com/news/3631946-regeneron-pharma-posts-strong-q3-driven-robust-dupixent-and-libtayo-sales